1. Home
  2. BY vs SNDX Comparison

BY vs SNDX Comparison

Compare BY & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BY

Byline Bancorp Inc.

HOLD

Current Price

$37.84

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$22.51

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BY
SNDX
Founded
1914
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
BY
SNDX
Price
$37.84
$22.51
Analyst Decision
Buy
Strong Buy
Analyst Count
2
13
Target Price
$36.00
$38.69
AVG Volume (30 Days)
353.5K
2.3M
Earning Date
04-23-2026
04-30-2026
Dividend Yield
1.48%
N/A
EPS Growth
5.09
11.56
EPS
0.83
N/A
Revenue
N/A
$172,352,000.00
Revenue This Year
$16.89
$107.19
Revenue Next Year
$3.15
$41.88
P/E Ratio
$45.63
N/A
Revenue Growth
N/A
627.84
52 Week Low
$25.38
$9.42
52 Week High
$38.88
$25.59

Technical Indicators

Market Signals
Indicator
BY
SNDX
Relative Strength Index (RSI) 61.86 54.42
Support Level $32.02 $22.40
Resistance Level $38.83 $25.38
Average True Range (ATR) 0.71 1.30
MACD -0.06 -0.13
Stochastic Oscillator 58.37 40.20

Price Performance

Historical Comparison
BY
SNDX

About BY Byline Bancorp Inc.

Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through a wholly-owned subsidiary of Byline Bank.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: